Table 2 Methodological characteristics
From: Systematic review of economic evaluations for paediatric pulmonary diseases
Lead author | Reference year | Type of economic evaluation | Trial or model based | Costing data | Sensitivity Analysis | Informed consent | Outcome measures | Study duration (months) | Discount rate | Hospitalisation costs (USD) | ICERS Δcosts (USD)/Δoutcome |
|---|---|---|---|---|---|---|---|---|---|---|---|
Duke, T [21] | 2021 | Cost analysis | Trial | Prospective | NR | NR | NA | 48 | NR | NR | NA |
Huang YM [22] | 2021 | Cost-utility analysis | Model | Prospective | Multi-way | NR | DALY averted | 12 | 3% | NR | 140 |
Kitano, T [23] | 2020 | Cost analysis | Trial | Prospective | NR | Stated- no informed consent | NA | 12 | NR | 1 421.40 | NA |
Chen, H. H. [24] | 2019 | Cost analysis | Trial | Retrospective | One-way | NR | NA | 12 | NR | 47.89 | NA |
von Schoen-Angerer, T. [25] | 2018 | Cost minimisation analysis | Trial | Prospective | NR | NR | NR | 18 | NR | NR | NA |
Ceyhan, M. [26] | 2018 | Cost analysis | Trial | Retrospective | Probabilistic | NR | NR | 12 | NR | 1 945.80 | NR |
Zhang, S [27] | 2017 | Cost-utility analysis | Trial | Retrospective | One-way | Stated- no informed consent | DALY averted | 12 | NR | NR | 34.33 |
Debes, A. K. [17] | 2017 | Cost-effectiveness analysis | Model | Retrospective | Multi-way | NR | Life years gained | NR | 3% | NR | 39 |
Bozzani, F. M. [28] | 2016 | Cost analysis | Trial | Retrospective | One-way | Stated- informed consent | NR | 3 | NR | 6.42 | NR |
Razi, C. H [29] | 2015 | Cost analysis | Trial | Retrospective | NR | Stated- informed consent | NR | 28 | NR | 299.00 | NR |
Andrews, A. L. [30] | 2015 | Cost-effectiveness analysis | Model | Prospective | Probabilistic | NR | ED visits averted | 12 | NR | 2 030.40 | NR |
Chu, S. M. [31] | 2015 | Cost analysis | Trial | Retrospective | NR | NR | NR | 30 | NR | NR | NR |
Floyd, J. [32] | 2015 | Cost-utility analysis | Model | Prospective | NR | NR | DALY averted | NR | NR | 6.44 | 11.63 |
Petrou, S. [33] | 2014 | Cost utility analysis | Trial | Prospective | NR | NR | QALY gained | 28 | NR | 285.36 | 337.02 |
Krebs, S. E. [34] | 2013 | Cost analysis | Trial | Prospective | NR | NR | NR | 12 | NR | 123.76 | NR |
Char, D. S. [35] | 2013 | Cost-effectiveness analysis | Trial | Prospective | NR | Stated- no informed consent | Complications avoided | > 48 | NR | NR | NR |
Powell, C. [36] | 2013 | Cost utility analysis | Trial | Prospective | NR | Stated- informed consent | QALY gained | NR | NR | 1 549.29 | 189 |
Andrews, A. L. [37] | 2012 | Cost-effectiveness analysis | Trial | Prospective | Two-way | NR | ED visits averted | NR | NR | 7 244.64 | NR |
Andrews, A. L. [38] | 2012 | Cost-effectiveness analysis | Trial | Prospective | Two-way | NR | ED visits averted | NR | NR | 7 244.64 | NR |
Doan, Q. [39] | 2011 | Cost-effectiveness analysis | Model | Retrospective | One-way | Stated- no informed consent | ED visits averted | NR | NR | 2 857.19 | -3 033.31 |
Broughton, E. I. [18] | 2011 | Cost utility analysis | Trial | Retrospective | One-way | NR | DALY averted | 24 | 3% | 280.17 | -396.00 |
Lorgelly, P. K. [40] | 2010 | Cost minimisation analysis | Trial | Prospective | One-way | NR | ED visits averted | 24 | NR | 870.46 | NR |